A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.
A 41-year-old male has been using a combination of treatments for hair regrowth, including finasteride, minoxidil, a laser cap, ketoconazole shampoo, and rosemary oil, with some progress noted. He is maintaining his current regimen in hopes of a future miracle drug while considering hair transplants and other treatments like dutasteride and copper peptides.
The user experienced significant hair regrowth after one month using oral Minoxidil, Finasteride, Dutasteride, Biotin, NMN, NMD, BPC-157, and topical Minoxidil, along with dermarolling. They expressed surprise at the effectiveness and regret not starting sooner, despite concerns about potential side effects.
Working outdoors does not affect the efficacy of oral hair loss drugs like finasteride and minoxidil. A user plans to start oral minoxidil and use a dermastamp.
Finasteride and dutasteride are discussed as preventative treatments for hair loss, with some advocating for early use and others concerned about side effects, especially before full maturity. Many regret not starting these treatments earlier due to their effectiveness in preventing or slowing hair loss.
Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.
Kopexil (Aminexil) is not approved as a drug in the US and Europe because it is marketed as a cosmetic, which requires less testing and regulation. L'Oreal's 1.5% Aminexil is noted to reduce hair shedding, but its efficacy as a drug is not proven.
PP405 may reactivate dormant hair follicles but won't replace hair transplants or resurrect dead follicles. Its effectiveness, cost, and impact compared to treatments like minoxidil and finasteride are uncertain.
Topical minoxidil may cause skin aging effects like wrinkles and dark circles, possibly due to its alcohol content, while oral finasteride is reported to make users look younger. Switching to oral minoxidil or using moisturizers might help reduce these skin issues.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
The conversation humorously discusses using off-label drugs like Minoxidil, finasteride, and RU58841 for hair growth. It jokes about the brain absorbing these treatments for maximum keratin production.
The conversation discusses affordable hair loss treatments, including oral dutasteride, oral and topical minoxidil, oral finasteride, 2% ketoconazole shampoo, and topical finasteride/minoxidil mixtures. Users share methods to obtain these drugs cheaply and legally.
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
The conversation is about someone using minoxidil, finasteride, RU58841, and microneedling for hair loss treatment for nearly two years with ongoing improvement. They are questioning the likelihood of continued hair regrowth over a four-year period.
Concerns about the long-term safety of Minoxidil and Finasteride for hair loss, with suggestions to weigh risks and consider cost-effective options like cutting higher-dose pills. Some users prefer Minoxidil due to perceived safety.
The conversation discusses why some people who use hard drugs have great hair, with various opinions suggesting genetics and higher estrogen levels as possible reasons. Specific treatments like Minoxidil, finasteride, and RU58841 are not mentioned.
The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.
Finasteride and minoxidil help maintain hair and slightly improve hairlines but are less effective at regrowing hair in bald areas, often needing a hair transplant for full restoration. Many users report no side effects and wish they had started treatment earlier.
A satirical post humorously discusses a fictional hair regrowth drug called PP405, with users joking about its effectiveness and bizarre presentation. The conversation includes humorous reactions and references to the absurdity of the content.
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
Korea launched its first OTC oral hair loss drug, dexpanthenol B5. Users discuss its anti-oxidative and anti-inflammatory effects but note a lack of efficacy studies.
The conversation is about a new acne treatment cream called Clascoterone Cream 1%, which is the first new mechanism of action for acne in nearly 40 years. One person joked about hoping their face will be as clean as their bald head after using the cream.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, RU58841, and Xeljanz. The user inquires about Xeljanz and shares a link suggesting it may help with hair loss.
Rob English, known for promoting scalp massages for hair regrowth, now sells his own brand of finasteride and minoxidil. Opinions are mixed, with some calling him a charlatan and others acknowledging his shift towards scientifically-backed treatments.
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.
A 24-year-old male experienced hair loss and successfully treated it using a combination of Finasteride, Dutasteride, and Oral Minoxidil. He reported no side effects and plans to continue the treatment to maintain his hair.
Finasteride and minoxidil are praised for effectively treating hair loss, with users sharing positive experiences and some discussing side effects. Others express concerns about limited treatment options and the need for more research and alternatives.